Accelerating Neurology Denial Appeal Automation

The Specifics of Neurology PA Denials

Neurology prior authorization often involves complex criteria for high-efficacy MS DMTs (e.g., ocrelizumab, natalizumab), CGRP migraine prevention biologics (e.g., erenumab, fremanezumab), and Alzheimer's anti-amyloid antibodies (e.g., lecanemab). Common denial reasons include step therapy requirements, gaps in amyloid biomarker confirmation, or insufficient documentation for chronic migraine criteria for Botox, directly impacting patient care and clinic revenue.

Key Denial Triggers in Neurology

• **MS DMT Step Therapy:** Payers frequently mandate trials of moderate-efficacy agents before approving high-efficacy DMTs, leading to denials when not followed.
• **Alzheimer's Anti-Amyloid Therapy:** Denials arise from missing amyloid confirmation (PET or CSF), inadequate MRI screening for ARIA, or non-compliance with APOE genotyping protocols.
• **CGRP Migraine Biologics:** Denials often stem from failure to document prior trials of oral preventive medications or insufficient headache diary data.
• **Botox for Chronic Migraine:** Lack of specific documentation proving chronic migraine criteria or prior preventive therapy failures can trigger denials.
• **Advanced Imaging:** Denials for brain MRI, MR angiography, or amyloid PET scans often relate to NCD/LCD-specific constraints or inadequate diagnostic justification.

Automating the Neurology Appeal Workflow

Klivira's platform integrates with your EMR to automate critical steps in the denial appeal process, from initial denial classification to final submission. This ensures that appeals for treatments like nusinersen/Spinraza for SMA or advanced epilepsy drugs like cenobamate/Xcopri are handled efficiently and accurately, reducing the administrative burden on your prior authorization coordinators and clinical staff.

Klivira's Automated Appeal Process for Neurology

• **Denial Classification:** Normalized CARC/RARC taxonomy routes denials for MS DMTs, CGRP biologics, or Alzheimer's therapies to the correct appeal pathway.
• **FHIR-Based Documentation Re-discovery:** Automatically pulls additional clinical evidence from the EMR, such as updated MRI findings, new lab results, or recent AAN Practice Guideline-aligned notes, to address documentation gaps.
• **Payer-Specific Appeal Letter Generation:** Composes appeal letters using per-payer templates that address the exact denial reason, with clinician-reviewable drafts for clinical-necessity appeals.
• **Timely-Filing Enforcement:** Automated tracking and escalation rules prevent timely-filing breaches for re-authorizations of chronic treatments or new appeals.
• **Status Tracking & Outcome Capture:** Monitors appeal status and writes outcomes back to the EMR, triggering downstream billing adjustments and providing valuable pattern feedback for upstream PA improvements.

Addressing Neurology-Specific Workflow Constraints

Neurology practices face unique challenges, including high volumes of specialty drug PAs, periodic re-authorization requirements for chronic conditions like MS, and ongoing MRI monitoring protocols. Klivira's platform is designed to manage these constraints, incorporating AAN-guideline-aware logic for step-therapy tracking and automating re-authorization workflows for treatments such as fingolimod biosimilars or Botox for spasticity.

Enhancing Compliance and Operational Efficiency

By leveraging Klivira for neurology denial appeal automation, organizations can ensure consistent appeal-letter quality, minimize lost-to-follow-up appeals, and adhere to payer-specific appeal pathways. This systematic approach reduces rework costs and accelerates approvals, allowing your team to focus on patient care rather than administrative overhead, while providing robust audit trails for compliance considerations.